Precigen, Inc.(PGEN)

Biotechnology · Germantown, MD

$7.58-0.17 (-2.13%)

Delayed quote: Oct 6, 2026, 3:25 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:27:33.482Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:27:33.482Z.

Quote observation: 2026-10-06T19:25:11.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 2,700,570,825
Total debt · period ending 2026-06-30: 98,345,000
Cash · period ending 2026-06-30: 16,329,000
TTM operating EBITDA · period ending 2026-06-30: -35,359,000

FMP input reference: a0072c9ba75a446a7d1e5aacfaaadbcfff4c6e87cd9201c0b7532283a182addc

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PGEN EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

PGEN Competitors' EV/EBITDA Ratio

PGEN

Precigen, Inc.

Current

Market Cap

$2.70B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACHC

Acadia Healthcare Company, Inc.

vs PGEN

Market Cap

$2.68B

EV/EBITDA Ratio

9.49x

TTM Avg

8.14x

3Y Avg

8.61x

5Y Avg

8.66x

ATRC

AtriCure, Inc.

vs PGEN

Market Cap

$2.73B

EV/EBITDA Ratio

75.65x

TTM Avg

85.01x

3Y Avg

85.01x

5Y Avg

85.01x

MBX

MBX Biosciences, Inc. Common Stock

vs PGEN

Market Cap

$2.66B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVAH

Aveanna Healthcare Holdings Inc.

vs PGEN

Market Cap

$2.64B

EV/EBITDA Ratio

13.08x

TTM Avg

11.53x

3Y Avg

20.03x

5Y Avg

19.21x

TMDX

TransMedics Group, Inc.

vs PGEN

Market Cap

$2.78B

EV/EBITDA Ratio

26.90x

TTM Avg

35.89x

3Y Avg

85.56x

5Y Avg

85.56x

NEOG

Neogen Corporation

vs PGEN

Market Cap

$2.61B

EV/EBITDA Ratio

32.15x

TTM Avg

28.10x

3Y Avg

22.56x

5Y Avg

30.37x

BEAM

Beam Therapeutics Inc.

vs PGEN

Market Cap

$2.59B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRVA

Privia Health Group, Inc.

vs PGEN

Market Cap

$2.57B

EV/EBITDA Ratio

N/A

TTM Avg

70.45x

3Y Avg

91.30x

5Y Avg

141.66x

DYN

Dyne Therapeutics, Inc.

vs PGEN

Market Cap

$2.87B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Precigen, Inc. (PGEN)	$2.70B	N/A	N/A	N/A	N/A
Acadia Healthcare Company, Inc. (ACHC)vs ›	$2.68B	9.49x	8.14x	8.61x	8.66x
AtriCure, Inc. (ATRC)vs ›	$2.73B	75.65x	85.01x	85.01x	85.01x
MBX Biosciences, Inc. Common Stock (MBX)vs ›	$2.66B	N/A	N/A	N/A	N/A
Aveanna Healthcare Holdings Inc. (AVAH)vs ›	$2.64B	13.08x	11.53x	20.03x	19.21x
TransMedics Group, Inc. (TMDX)vs ›	$2.78B	26.90x	35.89x	85.56x	85.56x
Neogen Corporation (NEOG)vs ›	$2.61B	32.15x	28.10x	22.56x	30.37x
Beam Therapeutics Inc. (BEAM)vs ›	$2.59B	N/A	N/A	N/A	N/A
Privia Health Group, Inc. (PRVA)vs ›	$2.57B	N/A	70.45x	91.30x	141.66x
Dyne Therapeutics, Inc. (DYN)vs ›	$2.87B	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics

About Precigen, Inc.

Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.

Germantown, MD

160 employees

www.precigen.com

Healthcare / Biotechnology